Pro-Dex (PDEX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Pro-Dex (PDEX) is set to announce its Q4 2025 earnings on Thursday, September 4th, with expectations of $0.47 earnings per share and $17.90 million in revenue.
• Analyst sentiment for PDEX remains mixed, with a consensus rating of "Buy" and varying price targets, including an increase from Ascendiant Capital Markets to $56.00.
• Institutional investors have been active, with notable increases in stakes from firms like Bank of America which grew its position by 173.3% in the second quarter.

Pro-Dex (NASDAQ:PDEX - Get Free Report) is expected to post its Q4 2025 results before the market opens on Thursday, September 4th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $17.90 million for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earningreport page for the latest details on the call scheduled for Friday, September 5, 2025 at 12:00 AM ET.

Pro-Dex Stock Performance

PDEX stock opened at $45.50 on Thursday. Pro-Dex has a 12-month low of $21.20 and a 12-month high of $70.26. The company has a current ratio of 2.73, a quick ratio of 1.45 and a debt-to-equity ratio of 0.28. The stock's 50 day simple moving average is $45.76 and its 200 day simple moving average is $46.30. The firm has a market cap of $148.33 million, a P/E ratio of 16.25 and a beta of 0.19.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PDEX. Ascendiant Capital Markets increased their price objective on Pro-Dex from $54.00 to $56.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Wall Street Zen lowered Pro-Dex from a "buy" rating to a "hold" rating in a report on Saturday, August 16th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Pro-Dex presently has a consensus rating of "Buy" and an average price target of $56.00.

Hedge Funds Weigh In On Pro-Dex

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in shares of Pro-Dex by 173.3% in the 2nd quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 1,073 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Pro-Dex in the 2nd quarter worth approximately $50,000. New York State Common Retirement Fund bought a new position in Pro-Dex during the second quarter valued at $105,000. JPMorgan Chase & Co. increased its position in Pro-Dex by 67.7% in the second quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier's stock worth $1,566,000 after buying an additional 14,479 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Pro-Dex by 93.2% during the second quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier's stock worth $2,255,000 after acquiring an additional 24,927 shares in the last quarter. Institutional investors own 15.28% of the company's stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.